Contributions
Abstract: PB1749
Type: Publication Only
Background
Cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) but their prognostic significance in these diseases is unknown. In this study, We assessed the association between changes in serum levels of interleukin-6, interleukin-10, and transforming growth factor beta cytokines baseline and after induction chemotherapy and the response to induction chemotherapy in patients with recently diagnosed previously untreated Acute Myeloid Leukemia (AML) patients.
Aims
To Assess the serum levels of IL-6, IL-10 and TGF beta in different types of newly diagnosed acute myeloid leukemia patients (FAB classifications) and the relationship between these cytokines and the laboratory findings and To determine the pre-and post-induction levels of these cytokines and their relationship to bone marrow blast cells.
Methods
This is a prospective case control study carried out on patients from Hematological Diseases Unit in internal Medicine Department, Assiut University Hospital and Medical Oncology Department, South Egypt Cancer Institute and clinical oncology and nuclear medicine department, Faculty of medicine , Assiut university. This study recruited 30 newly diagnosed patients with AML diagnosed by WHO classification and sub-classified (M1-M6) by FAB classification from February 2016 to May 2017. Mean age of the patients was 44 years (20-68). 30 patients (12 males and 18 females) as well as 20 age and sex matched healthy controls were also enrolled. Blood samples and estimation of serum levels of studied cytokines were collected from patients before induction and recollected again 10-14 days after induction and results were compared to its serum levels in 20 healthy control group (20 healthy individuals).The study was approved by the ethical committee of Faculty of Medicine, Assiut University. Informed Consents were obtained from the patients before enrollment in this study.
Results
Baseline serum levels of IL-6 and IL-10 levels were significantly higher in newly diagnosed AML patients than in control group (P-value=0.000*) suggesting their role in pathogenesis of the disease and their levels decreased when patients underwent remission (bone marrow blast cells count <5 %),with significant decrease in both responders and non- responders for IL-6 but regarding IL-10 there was a significant decrease only in responders (P-value=0.012*) and insignificant decrease in non-responders (P-value=0.2) .On the other hand, baseline TGF‑β level was significantly lower in newly diagnosed AML patients (before induction chemotherapy) than control group and its level significantly increased in patients responded to induction chemotherapy (P-value=0.012*) and insignificant increase in non-responders(P-value= 0.227).
Conclusion
Persistant Increased Serum level of IL-10 and persistant decreased TGF‑β level may be used as a prognostic marker for AML indicating poor response to induction chemotherapy and unfavorable prognosis.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Cytokine, IL-10, IL-6, TGF-
Abstract: PB1749
Type: Publication Only
Background
Cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) but their prognostic significance in these diseases is unknown. In this study, We assessed the association between changes in serum levels of interleukin-6, interleukin-10, and transforming growth factor beta cytokines baseline and after induction chemotherapy and the response to induction chemotherapy in patients with recently diagnosed previously untreated Acute Myeloid Leukemia (AML) patients.
Aims
To Assess the serum levels of IL-6, IL-10 and TGF beta in different types of newly diagnosed acute myeloid leukemia patients (FAB classifications) and the relationship between these cytokines and the laboratory findings and To determine the pre-and post-induction levels of these cytokines and their relationship to bone marrow blast cells.
Methods
This is a prospective case control study carried out on patients from Hematological Diseases Unit in internal Medicine Department, Assiut University Hospital and Medical Oncology Department, South Egypt Cancer Institute and clinical oncology and nuclear medicine department, Faculty of medicine , Assiut university. This study recruited 30 newly diagnosed patients with AML diagnosed by WHO classification and sub-classified (M1-M6) by FAB classification from February 2016 to May 2017. Mean age of the patients was 44 years (20-68). 30 patients (12 males and 18 females) as well as 20 age and sex matched healthy controls were also enrolled. Blood samples and estimation of serum levels of studied cytokines were collected from patients before induction and recollected again 10-14 days after induction and results were compared to its serum levels in 20 healthy control group (20 healthy individuals).The study was approved by the ethical committee of Faculty of Medicine, Assiut University. Informed Consents were obtained from the patients before enrollment in this study.
Results
Baseline serum levels of IL-6 and IL-10 levels were significantly higher in newly diagnosed AML patients than in control group (P-value=0.000*) suggesting their role in pathogenesis of the disease and their levels decreased when patients underwent remission (bone marrow blast cells count <5 %),with significant decrease in both responders and non- responders for IL-6 but regarding IL-10 there was a significant decrease only in responders (P-value=0.012*) and insignificant decrease in non-responders (P-value=0.2) .On the other hand, baseline TGF‑β level was significantly lower in newly diagnosed AML patients (before induction chemotherapy) than control group and its level significantly increased in patients responded to induction chemotherapy (P-value=0.012*) and insignificant increase in non-responders(P-value= 0.227).
Conclusion
Persistant Increased Serum level of IL-10 and persistant decreased TGF‑β level may be used as a prognostic marker for AML indicating poor response to induction chemotherapy and unfavorable prognosis.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Cytokine, IL-10, IL-6, TGF-